ABSTRACT
Lung adenocarcinoma (LUAD) has been the major cause of tumor-associated mortality in recent years and has a poor prognosis. Pyroptosis is regulated via the activation of inflammasomes and participates in tumorigenesis. However, the effects of pyroptosis-related lncRNAs (PRlncRNAs) on LUAD have not yet been completely elucidated. Therefore, we attempted to systematically explore patterns of cell pyroptosis to establish a novel signature for predicting LUAD survival. Based on TCGA database, we set up a prognostic model by incorporating PRlncRNAs with differential expression using Cox regression and LASSO regression. Kaplan–Meier analysis was conducted to compare the survival of LUAD patients. We further simplified the risk model and created a nomogram to enhance the prediction of LUAD prognosis. Altogether, 84 PRlncRNAs with differential expression were discovered. Subsequently, a new risk model was constructed based on five PRlncRNAs, GSEC, FAM83A-AS1, AL606489.1, AL034397.3 and AC010980.2. The proposed signature exhibited good performance in prognostic prediction and was related to immunocyte infiltration. The nomogram exactly forecasted the overall survival of patients and had excellent clinical utility. In the present study, the five-lncRNA prognostic risk signature and nomogram are trustworthy and effective indicators for predicting the prognosis of LUAD.
Highlights
A novel pyroptosis-related lncRNA signature was established.
Our signature improves the prediction of lung adenocarcinoma prognosis.
Pyroptosis might be associated with the immune response in lung adenocarcinoma.
Author’ s contributions
Ye Shi and Jiahang Song conceived and designed the original study. Jiahang Song, Zhengcheng Liu and Lei Xi collected the data. Jiahang Song, Hui Cao, Changqing Dong and Rusong Yang contributed to the interpretation of the data. Jiahang Song, and Yuanyuan Sun drafted the manuscript. Ye Shi revised the manuscript. All authors saw and approved the final version of the manuscript. These authors contributed equally: Jiahang Song, Yuanyuan Sun, Hui Cao.
Ethics approval and consent to participate
All data collection in studies involving human participants were in accordance with the ethical standards of the Cancer Genome Atlas Human Subjects Protection and Data Access Policies.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability
Publicly available datasets were analyzed in this study. These data can be found here: TCGA (https://portal.gdc.cancer.gov/).
Supplementary material
Supplemental data for this article can be accessed here.